Double-blind Cross-over Trial of Flurbiprofen and Phenylbutazone in Ankylosing Spondylitis
- 30 November 1974
- Vol. 4 (5943), 496-499
- https://doi.org/10.1136/bmj.4.5943.496
Abstract
A double-blind cross-over study in 35 patients with ankylosing spondylitis was carried out comparing flurbiprofen (150 mg daily)—a new non-steroidal anti-inflammatory agent—with phenylbutazone (300 mg daily) over a four-week period. Flurbiprofen was well tolerated and shown to have therapeutic efficacy approaching that of phenylbutazone. The results suggest that flurbiprofen may prove a valuable alternative in the treatment of ankylosing spondylitis, and longterm efficacy and tolerance studies are clearly indicated.Keywords
This publication has 5 references indexed in Scilit:
- " ANKYLOSING RHEUMATOID ARTHRITIS ", ANKYLOSING SPONDYLITIS, AND HL-A ANTIGENSThe Lancet, 1974
- Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis.Annals Of The Rheumatic Diseases, 1974
- Clinico-pharmacological studies and clinical evaluation of flurbiprofen. A new non-steroidal antirheumatic agent.Annals Of The Rheumatic Diseases, 1972
- Normal range of spinal mobility. An objective clinical study.Annals Of The Rheumatic Diseases, 1971
- THE FEET OF CLAY OF THE DOUBLE-BLIND TRIALThe Lancet, 1963